Literature DB >> 8894380

Soluble interferon-gamma receptors encoded by poxviruses.

A Alcamí1, G L Smith.   

Abstract

Poxviruses encode a broad range of proteins that counteract the formidable attack of the immune response initiated in the host after infection, among which are proteins that mimic the extracellular binding domain of host cytokine receptors and are secreted from virus-infected cells. A soluble interferon-gamma receptor (IFN-gamma R) is produced early after infection and efficiently blocks the binding of IFN-gamma to cellular receptors, thus inhibiting both the anti-viral and immune functions of IFN-gamma. An IFN-gamma R is highly conserved among members of the poxvirus family, suggesting a major role in viral pathogenesis. The highly species-specific nature of the IFN system enables questions concerning the evolutionary relationship between poxviruses and their hosts to be addressed. The IFN-gamma R encoded by myxoma virus, a natural pathogen of rabbits, is specific for rabbit IFN-gamma. However, the IFN-gamma R encoded by orthopoxviruses (vaccinia, cowpox, camelpox, ectromelia) shows a novel, broad species specificity suggesting that these viruses have evolved in several species. The implications for the unknown origin and natural host(s) of vaccinia virus are discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8894380     DOI: 10.1016/0147-9571(96)00013-6

Source DB:  PubMed          Journal:  Comp Immunol Microbiol Infect Dis        ISSN: 0147-9571            Impact factor:   2.268


  13 in total

1.  Activation of caspases in pig kidney cells infected with wild-type and CrmA/SPI-2 mutants of cowpox and rabbitpox viruses.

Authors:  J Macen; A Takahashi; K B Moon; R Nathaniel; P C Turner; R W Moyer
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

2.  Serp2, an inhibitor of the interleukin-1beta-converting enzyme, is critical in the pathobiology of myxoma virus.

Authors:  F Messud-Petit; J Gelfi; M Delverdier; M F Amardeilh; R Py; G Sutter; S Bertagnoli
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

3.  The unique C termini of orthopoxvirus gamma interferon binding proteins are essential for ligand binding.

Authors:  Anthony A Nuara; Hongdong Bai; Nanhai Chen; R Mark L Buller; Mark R Walter
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

4.  Interferon function is not required for recovery from a secondary poxvirus infection.

Authors:  Vijay Panchanathan; Geeta Chaudhri; Gunasegaran Karupiah
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-25       Impact factor: 11.205

5.  Inhibition of interferons by ectromelia virus.

Authors:  Vincent P Smith; Antonio Alcami
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

6.  Vaccinia virus blocks Stat1-dependent and Stat1-independent gene expression induced by type I and type II interferons.

Authors:  Brandon A Mann; Julia He Huang; Ping Li; Hua-Chen Chang; Roger B Slee; Audrey O'Sullivan; Mathur Anita; Norman Yeh; Michael J Klemsz; Randy R Brutkiewicz; Janice S Blum; Mark H Kaplan
Journal:  J Interferon Cytokine Res       Date:  2008-06       Impact factor: 2.607

Review 7.  Poxvirus homologues of cellular genes.

Authors:  J J Bugert; G Darai
Journal:  Virus Genes       Date:  2000       Impact factor: 2.198

8.  Stunned silence: gene expression programs in human cells infected with monkeypox or vaccinia virus.

Authors:  Kathleen H Rubins; Lisa E Hensley; David A Relman; Patrick O Brown
Journal:  PLoS One       Date:  2011-01-18       Impact factor: 3.240

9.  Lipid-nanoparticle-encapsulated mRNA vaccines induce protective memory CD8 T cells against a lethal viral infection.

Authors:  Cory J Knudson; Pedro Alves-Peixoto; Hiromi Muramatsu; Colby Stotesbury; Lingjuan Tang; Paulo J C Lin; Ying K Tam; Drew Weissman; Norbert Pardi; Luis J Sigal
Journal:  Mol Ther       Date:  2021-05-14       Impact factor: 12.910

10.  The highly virulent variola and monkeypox viruses express secreted inhibitors of type I interferon.

Authors:  María del Mar Fernández de Marco; Alí Alejo; Paul Hudson; Inger K Damon; Antonio Alcami
Journal:  FASEB J       Date:  2009-12-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.